Bellerophon Therapeutics, Inc. Expected to Earn Q1 2023 Earnings of ($0.47) Per Share (NASDAQ:BLPH)

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) – Investment analysts at HC Wainwright issued their Q1 2023 earnings per share (EPS) estimates for Bellerophon Therapeutics in a research report issued on Tuesday, April 4th. HC Wainwright analyst A. Fein anticipates that the biotechnology company will post earnings per share of ($0.47) for the quarter. HC Wainwright currently has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Bellerophon Therapeutics’ current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Bellerophon Therapeutics’ Q2 2023 earnings at ($0.47) EPS, Q3 2023 earnings at ($0.48) EPS, Q4 2023 earnings at $0.02 EPS, FY2023 earnings at ($1.40) EPS, FY2024 earnings at ($0.75) EPS, FY2025 earnings at ($0.27) EPS, FY2026 earnings at $0.49 EPS and FY2027 earnings at $1.63 EPS.

Get Bellerophon Therapeutics alerts:

Separately, StockNews.com initiated coverage on Bellerophon Therapeutics in a research note on Wednesday, March 29th. They set a “sell” rating on the stock.

Bellerophon Therapeutics Stock Down 10.5 %

BLPH opened at $10.20 on Thursday. The firm has a market cap of $106.59 million, a P/E ratio of -4.90 and a beta of 0.89. Bellerophon Therapeutics has a 52 week low of $0.67 and a 52 week high of $11.88. The business’s fifty day simple moving average is $4.43 and its 200 day simple moving average is $2.36.

Institutional Trading of Bellerophon Therapeutics

A hedge fund recently bought a new stake in Bellerophon Therapeutics stock. HRT Financial LP purchased a new position in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 28,035 shares of the biotechnology company’s stock, valued at approximately $25,000. HRT Financial LP owned about 0.29% of Bellerophon Therapeutics at the end of the most recent quarter. 11.36% of the stock is owned by institutional investors.

About Bellerophon Therapeutics

(Get Rating)

Bellerophon Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the development of products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Its product pipeline includes PH-ILD, PH-COPD, INOpulse and PH-Sarc. The company was founded in 2009 and is headquartered in Warren, NJ.

See Also

• Get a free copy of the StockNews.com research report on Bellerophon Therapeutics (BLPH)
• Hypercharge Networks: Up Triple Digits, But What’s The Big Deal? 
• 3 Reasons Why Apple’s 30% Rally Has Legs
• 3 Reasons to Pick First Citizens Instead of First Republic Bank
• 3 April Earnings Plays for Bullish Swing Traders
• Is Constellation Brands Star About To Rise? 

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.